Repulsive guidance molecules (RGMs) control crucial processes spanning cell motility, adhesion, immune cell regulation and systemic iron metabolism. RGMs signal via two fundamental signaling cascades: the Neogenin (NEO1) and the Bone Morphogenetic Protein (BMP) pathways. Here, we report crystal structures of the N-terminal domains of all human RGM family members in complex with the BMP ligand BMP2, revealing a novel protein fold and a conserved BMPbinding mode. Our structural and functional data suggest a pH-linked mechanism for RGMactivated BMP signaling and offer a rationale for RGM mutations causing juvenile hemochromatosis. We also determined the ternary BMP2-RGM-NEO1 complex crystal structure, which combined with solution scattering and live-cell super-resolution fluorescence microscopy, indicates BMP-induced clustering of the RGM-NEO1 complex. Our results show how RGM acts as the central hub linking BMP and NEO1 and physically connecting these fundamental signaling pathways.
INTRODUCTION
Repulsive guidance molecules (RGMs) are glycophosphatidylinositol (GPI)-anchored glycoproteins. There are three mammalian family members, RGMA, RGMB (also known as DRAGON) and RGMC (also known as hemojuvelin, HFE2). RGM dysfunction is linked to regenerative failure 1 , inflammation 2 , multiple sclerosis 3 , cancer 4 and blood diseases 5 . RGMs were initially discovered as a repulsive axon guidance cue 6 , where they signal by binding to the cell surface receptor neogenin (NEO1) 7, 8 , which belongs to the immunoglobulin superfamily and shares homology with the receptor deleted in colorectal cancer (DCC). We previously showed that this process is triggered by two RGM molecules that act as a molecular staple, bringing together the juxtamembrane regions of two NEO1 receptors, thus resulting in downstream signaling and actin cytoskeleton rearrangements 9 . All RGM family members have also been identified as co-receptors for the BMP morphogen pathway [10] [11] [12] , a process that was previously suggested to be modulated by NEO1 13, 14 .
BMPs comprise the largest subgroup of the Transforming Growth Factor β (TGFβ) superfamily and are key players in embryonic development and in the adult 15 . The active BMP signaling complex consists of the BMP ligand, a constitutive disulfide-linked dimer, concomitantly binding to the BMP type I and type II receptors. Four different BMP type I receptors (ALK1, ACVR1, BMPR1A and BMPR1B) and three BMP type II receptors (ACVR2A, ACVR2B and BMPR2) have been identified 16, 17 . Ligand binding triggers intracellular phosphorylation and activation of the type I receptor kinase domain by the constitutively active type II receptor kinase 18 . Subsequent downstream signaling occurs either via the SMAD signaling cascade 19 , or via less well characterized alternative pathways 20 . The cellular localization and the site of action of TGFβ and BMP receptors are still under debate and endocytosis has been shown to be important for TGFβ and BMP signaling 21 . BMP receptors (type I and II) undergo constitutive clathrin-mediated endocytosis even in the absence of the BMP ligand, resulting in a potentiation of SMADdependent BMP signaling upon BMP ligand exposure 22 . Moreover, BMPR2 is also internalized through caveolae and the balance between caveola-and clathrin-mediated endocytosis is suggested to modulate the patterns of gene transcription initiated by BMP signaling 22, 23 . In addition to receptor endocytosis, the BMP ligand itself can be readily internalized 24 and components of the SMAD signaling cascade are recruited to endosomal structures for activation 25 .
Multiple effector proteins act to regulate and fine tune spatio-temporal levels of BMP signaling at the membrane 26 . These include soluble secreted antagonists (such as Noggin, Chordin and the DAN or Cerberus protein family), transmembrane proteins (e.g. BAMBI and Endoglin) and the membrane-attached RGM family. RGMs are important co-receptors and activators for BMP signaling. RGMA and RGMB were initially identified in cellular BMP reporter assays 11, 12 . In addition, RGMB negatively regulates IL-6 expression in macrophages in a BMP ligand-dependent manner 27 . RGMC has been shown to enhance BMP signaling in liver cells to upregulate hepcidin expression and thereby control blood iron levels 10 , and mutations in RGMC cause the blood iron overload disease juvenile hemochromatosis (JHH) 5, 28, 29 , a pathology resulting from impaired BMP signaling 10, 30 . All RGMs can bind directly to BMPs with nanomolar affinities 31, 32 , however the molecular mechanism by which RGMs activate BMP signaling and the role of NEO1 in these processes remains unclear.
To elucidate the molecular mechanism of RGM-activated BMP signaling we solved crystal structures of BMP2 in complex with all human RGMs. Together with biophysical and cellular experiments, these structures suggest a mechanism for RGM-mediated activation of BMP signaling that is potentially linked to subcellular localization and offer a molecular rationale for JHH caused by RGM mutations. To address the role of NEO1 in these processes we determined the crystal structure of a ternary BMP-NEO1-RGM complex, which combined with X-ray solution scattering and quantitative super-resolution microscopic clustering analyses, provides direct evidence of a physical link between the NEO1 and BMP pathways bridged by RGMs, thus putting forward an important new mechanism for cellular signaling.
RESULTS

The structure of the BMP-RGM complex
We solved the crystal structure of human BMP2 in complex with the N-terminal domain of human RGMC (RGMC ND ) to 2.35 Å resolution (Fig. 1, Supplementary Fig. 1, 2 and Table  1 ). In the complex, two molecules of RGMC bind to one disulfide-linked BMP2 dimer (Fig.  1a-c and Supplementary Fig. 2 ). The RGMC molecules are related by a non-crystallographic pseudo-twofold axis and have an r.m.s.d. of 0.73 Å for 66 equivalent Cα positions. RGMC ND adopts a novel fold composed of a triple helix bundle stabilized by three disulfide bonds (Fig. 1b, c, d and Supplementary Fig. 3a, b) . RGMC ND binds to the "finger" region of BMP2, interacting with both BMP2 molecules ( Fig. 1d-f ). The RGM interface on BMP2 is highly conserved in all vertebrate BMP2, BMP4, BMP6 and BMP7 family members ( Fig. 1e and Supplementary Fig. 1 ). RGMC contacts both molecules of the disulfide-linked BMP2 dimer (total buried surface area of 1690 Å 2 ), an interaction that displays mixed electrostatics (6 hydrogen bonds, and 105 non-bonded contacts, Fig. 1f ).
RGMA and RGMC contain a conserved RGD motif (traditionally known to be important in integrin-fibronectin mediated adhesion 33, 34 ). This motif, containing RGMC residues R98, G99 and D100, located in a loop region between helices α2 and α3, forms a major interaction site with BMP2 (Fig. 2a, b , residues highlighted by asterisks). Specifically, RGMC residues R98 and G99 provide several hydrogen bonds and non-bonded contacts (Fig. 2b) , thereby positioning RGMC-H104 to allow the formation of a π-stacking interaction with BMP2-W313 (Fig. 2c) . This arrangement is further stabilized by a Tshaped, orthogonal π-stacking between BMP2 residues W313 and W310. Intriguingly, mutations of RGMC residues G99 (of the proposed RGD motif) and L101, located in the center of the BMP-binding interface, cause the severe iron overload disease JHH 5, 28, 35 (Fig  2b) .
To validate our structural data, we carried out surface plasmon resonance (SPR) equilibrium binding experiments (Fig. 2d-g ). Our SPR analysis revealed a level of non-specific interaction between RGMs and BMP2, an effect that was markedly decreased for the Nterminal domain RGM constructs. Both the full length RGM ectodomain constructs (eRGMA, eRGMB, eRGMC) and the RGM N-terminal domain constructs (RGMA ND , RGMB ND , RGMC ND ) bound to BMP2 with nanomolar affinities (the tightest being RGMB ND (K d 88 nM)) demonstrating that the RGM N-terminal domain is sufficient for interaction with BMP2 (Fig. 2d, e and Supplementary Fig. 4 ). In addition, mutation of RGMC-H104 to alanine impaired binding to BMP2 (From K d 124 nM to K d 280 nM) (Fig.  2e, Supplementary Fig. 4f, g ). This confirmed that the conserved RGMC-H104 is important for efficient complex formation through a π-stacking interaction with BMP2-W313; a similar behavior was observed for the RGMB-H106R mutation ( Supplementary Fig. 4l ).
We also solved the crystal structures of BMP2 in complex with the N-terminal domains of human RGMA and RGMB (RGMA ND and RGMB ND , respectively) (Fig. 3, Table 1 ). A structural superposition revealed that the overall complex architecture (Fig. 3a) and BMP2-binding mode (Fig. 3b-e) is highly conserved across all RGM family members and in all species ( Supplementary Fig. 1 ), demonstrating a common mode for the BMP-RGM interaction.
The RGMC-BMP2 structure offers a rationale for JHH mutations JHH is an autosomal-recessive iron overload disorder that results in cardiomyopathy and diabetes. JHH is caused by a deficiency in the levels of hepcidin, whereas an excess of hepcidin is linked to anemia of inflammation 36, 37 . RGMC-activated BMP signaling is crucial for upregulation of hepcidin expression and control of serum iron level, and mutations in RGMC are the major cause of JHH 5, 10 . Most of these mutations are located in the C-terminal domain of RGMC, the region responsible for NEO1 binding (Fig. 1a) 9 . These mutations impair protein secretion in mammalian cells, whereas mutations located in the RGMC N-terminal domain do not affect secretion 9, 38 . Here, we show that two of these, RGMC-G99R and -L101P are located in the interface with BMP2 and reduce the affinity of the RGMC-BMP2 interaction (K d 910 nM, 1.5 μM respectively) (Fig. 2f, g and Supplementary Fig. 4h, i) . This not only validates the interface observed in our RGM ND -BMP2 structures, but also suggests that disruption of the BMP-RGMC interaction is the molecular mechanism for JHH disease pathology. Taken together, our analysis may provide a basis for the structure-guided design of novel therapeutics for the treatment of iron related disorders such as hemochromatosis and anemia of inflammation.
RGM competes with the BMP type I receptor for BMP2-binding
Crystal structures of BMP ligands with their respective receptor ectodomains have revealed a common mode of binding in which two BMP type I and II receptor molecules bind independently to a BMP dimer in a symmetric arrangement [39] [40] [41] . In our RGM-BMP2 structures, RGM ND unexpectedly shares an overlapping BMP2-binding interface with the ectodomain of the BMP type I receptor BMPR1A (eBMPR1A; Fig. 4a, b) , however the BMP type II receptor (eBMPR2, eACVR2A) binding site does not overlap (Fig. 4a) . To confirm this observation drawn from our structural analysis, we carried out a series of SPR experiments. The secreted ectodomain of BMPR1A (eBMPR1A) bound to BMP2 with a K d of 280±10 nM (Fig. 4c ), in agreement with previous studies 42 and comparable to the RGMB-BMP2 interaction ( Supplementary Fig. 4b, e) . In this experimental setup, we did not detect specific binding between eRGMB and BMP receptor ectodomain constructs (eBMPR1A, eBMPR2, eACVR2A) ( Supplementary Fig. 4p-r) , in contrast to previously reported pull-down experiments with full-length BMP receptors 11 . Next, we tested the ability of eBMPR1A to compete with eRGMB for BMP2 binding (Fig. 4d) . We observed that a 1.7 times molar excess of eBMPR1A was required to displace eRGMB in solution suggesting that eRGMB effectively competes with eBMPR1A for BMP binding as expected from our structural data.
The RGM-BMP2 interaction is pH-dependent
Although the structures of eBMPR1A and RGM ND are distinct, both share a common helix located at the interface with BMP2 (Fig. 4a, b) , which is part of the BMPR1A epitope previously identified to be crucial for BMP2 interaction 43 . In this key helix, RGMB-H106 (corresponding to RGMC-H104) occupies the equivalent position to BMPR1A-F108. Both residues are involved in π-stacking interactions with BMP2 residues W310 and W313 (Fig.  3c, 4b and 2d, e) . With the hypothesis that the protonation state of RGMB-H106 might affect the BMP2-W313 π-stacking, we performed multi-angle light scattering (MALS) measurements of both BMP2-RGMB ND and BMP2-eBMPR1A complexes at different pH values (Fig. 4e, f) . For BMP2-RGMB ND , we observed a major species at neutral pH with a molecular weight corresponding to the 2:2 BMP2-RGM ND complex, whereas at pH 6.5 or lower, dissociation of the complex occurred (Fig. 4e ). Our data showed that the BMP2-RGMB ND interaction is pH dependent, whereas the binary 2:2 BMP2-eBMPR1A complex is not (Fig. 4f ).
RGMB and BMPR1A differentially alter BMP signaling
How does RGM activate BMP signaling when it competes with the canonical BMP binding mode for BMP type I receptors? In order to answer this, we conducted a BMP-responsive luciferase reporter (BRE-Luc) assay in LLC-PK1 cells 11, 44 . Stimulation with 6 nM purified BMP2 increased BRE-luciferase activity ~5-fold (n=40, P<0.0001) over the control (Fig.  4g ). When we transfected cells with full-length (GPI-anchored) RGMB, BRE luciferase activity was further enhanced ~3-fold (n=40, P<0.0001) (Fig. 4g ), comparable to published results 11 , whereas transfection with a GPI-anchored RGMB construct lacking the RGMB ND domain (RGMB ΔN ) had no effect (n=40, P=0.0509) on the BMP-induced response (Fig. 4g ). This confirmed that the N-terminal domain is necessary for this activation, in agreement with our structural and SPR analysis (Fig. 3d , e and Supplementary Fig. 4j ).
Next, we investigated the effects of soluble proteins (lacking the membrane attachment sites) in the same luciferase reporter assay (Fig. 4h , and Supplementary Fig. 5 ). Stimulation with 6 nM purified BMP2 increased BRE-luciferase activity ~10-fold (n=72, P<0.0001) over the control (n=37) (Fig. 4h) . When we transfected cells with soluble eBMPR1A, BRE luciferase activity decreased to ~75% (n=22, P<0.0001). In contrast, transfection with soluble eRGMB and RGMB ND did not reduce BRE luciferase activity (n=22, P=0.8606; n=24, P=0.992 respectively) ( Fig. 4h , and Supplementary Fig. 5 ), contrasting with previous studies using a RGMB-Fc fusion construct 11 . To further validate our observation, we performed similar experiments, but now added purified eBMPR1A or eRGMB proteins directly to LLC-PK1 or C2C12 cells ( Supplementary Fig. 5 ). Again, we observed inhibition of BMP signaling by eBMPR1A, whereas eRGMB did not inhibit BMP2 signaling in either cell type, even at concentrations (2.5 μM) three times the K d for the eRGMB-BMP2 interaction ( Supplementary Fig. 5 ). In summary, soluble BMPR1A ectodomain acts as a "ligand-trap", competing with endogenous BMP type I receptors and inhibiting signaling, as expected. Surprisingly however, we found that this behavior does not extend to soluble RGMB proteins that nonetheless have similar binding affinities and can compete with the BMPR1A-BMP2 interaction. This finding, linked with the pH dependence of the RGMB-BMP2 interaction may imply an endocytosis-linked mechanism of RGM-activated BMP signaling.
The structure of the ternary BMP-RGM-NEO1 complex
To place the RGM-BMP2 interaction into the context of the RGM-NEO1 signaling hub 9 , we next determined the crystal structure of the ternary complex composed of BMP2, eRGMB and the juxtamembrane region of NEO1 including the fifth (FN5) and sixth (FN6) fibronectin type III domains (Fig. 5a, b) . In the complex, a disulfide-linked BMP2 dimer binds to two molecules of RGMB ND in a very similar arrangement to that observed in the binary BMP2-RGMB ND complex (r.m.s.d. of 0.799 Å for 328 equivalent Cα positions) ( Supplementary Fig. 6a ). Each RGMB ND is connected to the RGMB C-terminal domain (RGMB CD ) via a disordered 15 amino acid linker not visible in the electron density map. RGMB CD interacts with NEO1 via a similar mode to that observed for the major interaction site in the previously determined eRGMB-NEO1 complex structure 9 (r.m.s.d. of 0.511 Å for 368 equivalent Cα positions) ( Supplementary Fig. 6a ). In the ternary complex, the FN5 domain of NEO1 also contacts BMP2 (Fig. 5a ). However, analysis of the observed interfaces ( Supplementary Fig. 6b ) suggests that this NEO1-BMP2 interaction is due to crystal packing rather than an important biological interface, which is in agreement with the fact that binding affinities of BMP2 to eRGMB or the purified eRGMB-NEO1 complex were similar and that there was no increase in affinity contributed by NEO1 ( Supplementary  Fig. 4k ).
To test whether a similar arrangement of the RGMB-NEO1-BMP2 complex exists in solution we carried out small-angle X-ray scattering (SAXS) experiments of the eRGMB-NEO1-BMP2 complex and its components ( Fig. 5c and Supplementary Fig. 7 ). The eRGMB-NEO1-BMP2 complex, prepared via size exclusion chromatography ( Supplementary Fig. 7a, b ), resulted in a particle of a mass consistent with the ternary complex in a 2:2:2 stoichiometry. Starting from the crystal structure, we generated ensembles of RGMB-NEO1-BMP2 models by molecular dynamics sampling and selected these against the SAXS data. The solution structure can be accurately described (χ 2 =1.9) as a mixture of two models that have architectures similar to the crystal structure, but which show structural variation only at the level of the linker that connected RGMB ND and RGMB CD , thereby dislocating the NEO1-FN5 domain away from BMP2 ( Fig. 5c ) and thus supporting our analysis of the observed interfaces in this complex interaction network ( Supplementary Fig. 6b ).
BMP mediates clustering of RGM-NEO1 at the cell surface
In the ternary complex, the two RGM and NEO1 molecules are orientated in such a way that the C-termini (that, in the context of the full-length proteins, are connected with the lipid bilayer of the plasma membrane) point in the same direction (Fig. 5b) . This arrangement, also observed in solution, combined with the active signaling conformation of the 2:2 complex between NEO1 and the C-terminal domain of RGM 9 suggests a mode of clustering in which RGM bridges the dimers of BMP and NEO1, respectively (Fig. 5d) . Indeed, total internal reflection fluorescence microscopy (TIRFM) combined with direct stochastic optical reconstruction microscopy (dSTORM) 45 in COS7 cells (Fig. 6a, b) revealed an increase in the clustering of fluorescently-tagged NEO1 molecules in a time-dependent manner after the addition of 20 nM BMP2 using live (Fig. 6a-f ) and fixed (Fig 6g, h ) cells, respectively. This clustering was dependent on the presence of full-length RGMB and reached a maximum ~15 minutes after addition of BMP2 (Fig. 6e-h ).
DISCUSSION
RGMs can signal through both trans (intercellular) 9 and cis (same cell) interactions. Cis signaling occurs in a BMP-dependent manner, such as in chondrocytes 46 and hepatocytes 14 , when both NEO1 and RGM are expressed on the same cell surface. Although the role of NEO1 in BMP signaling is still unclear and cell type dependent 47 , multiple lines of evidence point towards a central role for the NEO1-RGM interaction in controlling BMP ligandreceptor localization. In hepatocytes, NEO1 inhibits RGMC shedding, thus enhancing BMP signaling and hepcidin expression in the liver 13, 14 . This is in agreement with our results where high local RGM concentrations were required for activation of BMP in a luciferase reporter assay (Fig. 4g, h ), which are, in vivo, likely only provided by membrane attachment of RGMs to BMP-responsive cells. Furthermore, SMAD-dependent BMP signaling is reduced in chondrocytes in NEO1-deficient mice, further suggesting that NEO1 regulates BMP receptor localization with RGMs potentially acting as a protein scaffold that could support a BMP receptor super-complex in membrane microdomains 46 . It is interesting to note that NEO1 is located in membrane microdomains in growth cones of axons, a process that is dependent on the presence of both RGM and BMP signaling 48 . Our structural and functional data identifies the RGM N-terminal domain as being the site of direct interaction for the BMP ligand. This interaction is accommodated in the multi-domain architecture of our NEO1-RGM-BMP2 ternary complex structure, which allows simultaneous binding of RGMs to NEO1 and BMP ligands and results in RGM-mediated clustering by bridging dimers of NEO1 and BMP2.
Our luciferase reporter data, together with the pH-dependence of the RGMB-BMP2 interaction, suggests a potential mechanism for RGM-mediated activation of BMP signaling. We showed that soluble eBMPR1A acts as an inhibitor of BMP signaling, whereas eRGMB does not. We propose that this difference is linked to the pH-dependence of the RGMB-BMP2 interaction and the subcellular localization of the BMP signaling complexes. Upon clathrin-mediated endocytosis BMP2-RGMB complexes might be targeted into endosomes, which are enriched with BMP type I receptors 22 . The acidification of the endosomes might then promote dissociation of RGMB from the complex and replacement by the BMP type I receptor leading to enhanced BMP signals, due to potentiation of SMAD signaling provided by the endosomal environment compared to the cell surface 21, 22 . In this scenario, the RGM-NEO1 complex could act as a shuttle for the BMP ligand (and potentially BMP type II receptors, which can be accommodated in our RGM-NEO1-BMP complex). The RGM-NEO1 complex potentially sequesters the BMP ligand at the membrane, priming it for transport via endosomal pathways. Future work will be required to test our hypothesis, linking RGMs to BMP endocytosis, and to characterize this in different biological contexts. Translocation of the signaling machinery through established pathways to place it in close proximity to the nucleus, and thus downstream effector targets, is a very efficient way of effecting changes in gene expression. This mechanism has been suggested for other signaling pathways including the closely related TGFβ signaling 21 as well as epidermal growth factor (EGF) 49 and glial-cell derived neurotrophic factor (GDNF) signaling 50 . The molecular mechanism of RGM-mediated BMP activation, based on endocytosis of the entire signaling complex may provide a paradigm for many "cell-surface" signaling events. 54) ), fused C-terminally with either a hexa-histidine, a BirA recognition sequence or a mVenus tag, were cloned into the pHLsec vector 55 and expressed by transient transfection in HEK-293T cells (ATCC CRL-11268) (using a semi-automated procedure 56 ) in the presence of the class I α-mannosidase inhibitor, kifunensine 57 . Five days post-transfection, the conditioned medium was dialyzed (48 h, 4 °C) against PBS and the proteins were purified by immobilized metalaffinity chromatography using TALON beads (Clontech) and, for crystallization, treated with endoglycosidase F1 (75 μg mg −1 protein, 12 h, 21 °C) to cleave glycosidic bonds of Nlinked sugars resulting in only one N-acetyl-glucosamine moiety bound to the corresponding asparagine side chain. The proteins were concentrated and further purified by size-exclusion chromatography (SEC) (Superdex 200 16/60 column, GE Healthcare) in buffer containing 10 mM HEPES, pH 7.5, 150 mM NaCl. The production of NEO1 FN56 and NEO1 FN56M followed a protocol described in 54 .
ONLINE METHODS
Expression and purification of BMP2 and formation of protein complexes
BMP2 was expressed as inclusion bodies and purified as follows (protocol adapted from 58 ). After cell lysis, inclusion body pellets were washed four times with 20 mM EDTA, 2% (v/v) Triton X-100, 500 mM NaCl, pH 7 and then solubilized in 6 M guanidinium hydrochloride (GdmHCl), 0.1 M Tris-HCl, pH 8.5, 1 mM EDTA and 100 mM DTT. The pH was dropped to 3-4 to inhibit disulfide bond formation. Residual insoluble material was removed by centrifugation (10 min, 10,000 g, 4 °C). DTT was removed by dialysis four times against 10-to 20-fold volume of 6 M GdmHCl, pH 3-4. Refolding was carried out by incubating the reduced and solubilized inclusion body preparation (24 h, 4 °C, ~200 μg/ml concentration) in 100 mM Tris-HCl, 5 mM EDTA, 1 M L-arginine, pH 8.3, 100 μM oxidized glutathione (GSSG), 100 μM reduced glutathione (GSH). The sample was concentrated to 1 mg/ml using Amicon pressure filtration (Millipore) and the reaction split into two halves, one of which was oxidized with 25 mM GSSG (3 h, 4 °C). Excess GSSG was removed by dialysis and the two reaction halves were combined. This sample was concentrated and applied to a heparin column (5 ml HiTrap Heparin HP, GE Healthcare) followed by SEC in 4 M Urea, 100 mM Tris-HCl, pH 6.0, 5 mM EDTA. SEC fractions were analyzed by non-reducing SDS-PAGE and those with a purity > 95% of the dimeric species were pooled. BMP2-RGM ND complexes were formed by mixing the proteins in a 1:1 molar ratio. For the tertiary BMP2-eRGMB-NEO1 FN56 complex, BMP2 was mixed in equimolar amounts with a previously SEC-purified eRGMB-NEO1 FN56 complex. The complex mixtures were incubated for 1 hour at room temperature prior to crystallization and concentrated to the appropriate concentration.
Site directed mutagenesis
Site-directed mutagenesis of RGM proteins to test specificity of protein-protein interactions was carried out by two-step, overlap-extension PCR using Pyrobest Polymerase (Takara). PCR products were cloned into the pHLsec vector as above 55 . Mutant RGM proteins were secreted at similar levels to the respective wildtype constructs (data not shown). The stringent quality control mechanisms specific to the mammalian cell secretory pathway is likely to ensure that secreted proteins are correctly folded 59 .
Crystallization and data collection
Prior to crystallization, complexes were concentrated (RGMA ND -BMP2: 6 mg/ml, RGMB ND -BMP2: 6 mg/ml, RGMC ND -BMP2: 5 mg/ml and BMP2-eRGMB-NEO1 FN56 : 5 mg/ml). Crystallization trials, using 100 nl protein solution plus 100 nl reservoir solution in sitting drop vapor diffusion format were set up in 96-well Greiner plates using a Cartesian Technologies robot 60 . Crystallization plates were maintained at 6.5 or 20.0 °C in a TAP Homebase storage vault and imaged via a Veeco visualization system 61 . All binary RGM-BMP2 complex crystals were grown at 6.5 °C, whereas the ternary BMP2-eRGMB-NEO1 FN56 ) and I04-1 (RGMB ND -BMP2 Form-2) at the Diamond Light Source, UK. X-ray data were processed and scaled with the HKL suite 62 and XIA2 [63] [64] [65] [66] [67] [68] . Data collection statistics are shown in Table 1 .
Structure determination and refinement
The RGMC ND -BMP2 complex was solved by molecular replacement in PHASER 69 using the structure of the disulfide bonded BMP2 dimer (PDB 3BMP 70 ) as a search model. Extra electron density for two molecules of RGMC ND in the asymmetric unit was immediately discernible after density modification in PARROT 71 ( Supplementary Fig. 2a, b) . The RGMC polypeptide chain was traced using iterative rounds of BUCCANEER 72 , manual building in COOT 73 and refinement in autoBUSTER 74 and PHENIX 75 . This resulted in a well-defined model for the RGMC ND -BMP2 complex that included two molecules of RGMC (residues Q36-P129) bound to a disulfide linked BMP2 dimer (residues K293-R396) (Supplementary Fig. 2c ). The RGMA ND -BMP2 and RGMB ND -BMP2 complexes were solved by molecular replacement using PHASER with the RGMC ND -BMP2 complex as a search model. Molecular replacement with PHASER was applied to solve the BMP2-eRGMB-NEO1 FN56 structure using the RGMB ND -BMP2 Form 1 (from this study) and the NEO1 FN56 -RGMB (PDB ID. 4BQ6 54 ) structures. The complexes were refined using autoBUSTER 74 and PHENIX 75 and, where applicable, non-crystallographic restraints were applied. For the BMP2-eRGMB-NEO1 FN56 structure target weight refinement using the individual high resolution structures of the BMP2, RGMB ND , eRGMB, NEO1 FN5 and NEO1 FN6 domains as targets was applied. Crystallographic statistics are given in Table 1 . Stereochemical properties were assessed by MOLPROBITY 76 . Superpositions were calculated using the program COOT 73 and electrostatic potentials were generated using APBS 77 as implemented in PYMOL 78 . Buried surface areas of protein-protein interactions were calculated using the PISA webserver 79 for a probe radius of 1.4 Å.
Small-Angle X-ray scattering (SAXS)
Data were collected at beamline BM29 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) 80 at 293 K within a momentum transfer (q) range of 0.01 Å −1 < q < 0.45 Å −1 , where q = 4πsin(θ)/λ and 2θ is the scattering angle. X-ray wavelength was 0.0995 nm and data were collected on a Pilatus 1M detector. Protein samples were measured at the following concentrations: NEO1 FN56M : 1.06 and 4.94 mg/ml, eRGMB: 0.96 and 5.48 mg/ml, NEO1 FN56M -eRGMB: 0.51 and 1.01 mg/ml, and BMP2-eRGMB-NEO1 FN56M : 0.68 and 1.14 mg/ml. Data reduction and calculation of invariants was carried out using the ATSAS software suite 81 . A merged dataset was obtained by combining the low-angle part of the low-concentration dataset with the high-angle part of the high-concentration dataset. Molecular weight determination was performed using the volume of correlation metric V C using Scatter 82 . The BMP2-eRGMB-NEO1 FN56M solution structure was modeled starting from the crystal structure of the ternary complex. A structural model for C-terminal eRGMB residues His335-Ser410 (not observed in the electron density) was calculated using ROSETTA3.5 (ref. 83) , constrained by imposing alpha-helical secondary structure and a disulfide bond between Cys358 and Cys372. Missing loops and N-and C-termini were added in extended conformations using Modeller 84 . Starting models for NEO1 FN56M , eRGMB, and the eRGMB-NEO1 FN56M binary subcomplex were then extracted from the completed BMP2-eRGMB-NEO1 FN56M model. All-atom ensemble modeling of NEO1 FN56M , eRGMB, eRGMB-NEO1 FN56M and BMP2-eRGMB-NEO1 FN56M was performed using AllosMod 85 ; and in each case, 50 independent ensembles of 100 models were generated. From this pool, automated selection of the minimal set of models satisfying the scattering data was performed using MES 86 , and calculation and fitting of scattering patterns was performed using FoXS 87 . This procedure was automated using the AllosModFoXS web server 88 . The solution structures of NEO1 FN56M , eRGMB, eRGMB-NEO1 FN56M and BMP2-eRGMB-NEO1 FN56M are described by one, one, three and two models, respectively.
Multiangle light scattering (MALS)
MALS experiments were carried out using a DAWN HELEOS II (Wyatt Technology), equipped with a K5 flow cell and a 30 mW linearly polarized GaAs laser with a wavelength of 690 nm. Proteins used for MALS contained wild-type sugars. Proteins were purified by SEC and the BMP2-RGMB ND and BMP2-eBMPR1A complexes were formed by mixing the components in a 1:1 molar ratio. Complexes were dialyzed against buffers generated using the MMT buffer system (Malic acid, MES, Tris; Molecular Dimensions): 10 mM MMT, pH 5.5/6.5/7.5, 150 mM NaCl. Complexes were concentrated to 2 mg/ml prior to MALS analysis. Data were analyzed using ASTRA (Wyatt Technologies) and molecular weights were calculated using the Debye fit method. Molecular weights were calculated as: BMP2-RGMB ND /pH 7.5: 46.2±2.7, 22.4±0.9; BMP2-RGMB ND /pH 6.5: 20.1±1.4, 13.4±0.4; BMP2-RGMB ND /pH 5.5: 24.0±1.2, 16.2±0.3; BMP2-eBMPR1A/pH 7.5: 53.0±0.1, 15.0±0.2; BMP2-eBMPR1A/pH 6.5: 53.2±0.3, 18.8±0.1; BMP2-eBMPR1A/pH 5.5: 54.2±0.5, 19.7±0.4. These molecular weights correspond to the calculated masses: BMP2-RGMB ND : 47 kDa, BMP2: 26 kDa, RGMB ND : 11 kDa, BMP2-eBMPR1a: 53 kDa, eBMPR1a: 14 kDa. Graphs were produced using GraphPad Prism Version 6.04 (GraphPad Software, La Jolla California USA).
Surface plasmon resonance (SPR) binding studies
SPR experiments were performed using a BIAcore T200 machine (GE Healthcare) at 25 °C in SPR running buffer (10 mM HEPES, pH 7.5, 150 mM NaCl, 0.005% (v/v) polysorbate 20). All experiments were performed using direct protein immobilization by amine coupling to CM5 biosensor chips except for Supplementary Fig. 4p -r, where biotinylated eRGMB was immobilized onto streptavidin-coupled CM5 biosensor chips 89 . Analytes were dialyzed against SPR running buffer prior to use, and 1 in 2 dilution series were prepared. For the competition experiment a 1 in 2 dilution series of a mixture of 20 μM eBMPR1A and 2.5 μM eRGMB was prepared in buffer containing 2.5 μM eRGMB, resulting in a dilution series of eBMPR1A in a constant (2.5 μM) concentration of eRGMB. BMP2 surface concentrations were 150, 500 and 1000 response units. Surfaces coupled with BMP2 were regenerated by bursts of 4 M Urea, 50 mM Tris pH 8.0, 150 mM NaCl (120s, 20 μl/min) and the experimental trace returned to baseline. In all experiments error range, s.e.m. (n = 2 technical replicates). The signal from experimental flow cells was corrected by subtraction of the nearest blank injection and the reference signal from a blank flow cell. All data were analyzed using SCRUBBER2 (Biologic) and GraphPad Prism Version 6.04 (GraphPad Software, La Jolla California USA). Best-fit binding curves were calculated for BMP2 -BMP receptor interactions using non-linear curve fitting of a "one-site specific binding" model (Y=B max *X/(K d +X), X=analyte concentration, B max =maximum analyte binding). For BMP2-RGM binding, best-fit curves were calculated using non-linear curve fitting of a "one-site total binding" model (Y=B max *X/(K d +X)+NS*X+Background, X=analyte concentration, Background=0 as data were already referenced), non-specific binding is proportional to analyte concentration and therefore NS is the slope of non-specific binding. B max and K d values were determined for the specific binding component only. For the eBMPR1A-eRGMB competition experiment a best-fit binding curve was calculated using a "log(agonist) vs response variable slope" model (Y=Bottom+(Top-Bottom)/ (1+10^((LogEC50-X)*HillSlope)), X=analyte concentration, top=Y max , bottom=Y min , EC50 is the concentration of agonist that gives a response half way between bottom and top). The HillSlope parameter was constrained to 1.0. An R 2 value to quantify goodness of fit (range 0-1.0) and an IC 50 value were reported.
Luciferase reporter assay
LLC-PK1 cells, or C2C12 cells stably transfected with a BRE-luciferase reporter plasmid 90 , were plated in complete DMEM supplemented with 10% FBS at a density of 5 × 10 4 cells/ml in a 96-well plate (100 μl/well) (Nunc-Immuno ™ MicroWell ™ 96 well polystyrene plates, Sigma-Aldrich). After 24 h LLC-PK1 cells were transfected using Lipofectamine 2000 transfection reagent (Lifetechnologies) according to manufacturer's protocol, with 40 ng pGL3 BRE-Luciferase plasmid 91 , 30 ng Renilla control plasmid and, where indicated, 20 ng of empty pHLSec vector control or test constructs as indicated. Eight hours posttransfection the cells were washed with PBS (100 μl) and serum starved in complete DMEM supplemented with 0.1% FBS overnight. Cells were stimulated with 6 nM, 10 nM or 25 nM BMP2 as indicated or buffer. Where soluble proteins were directly added to the cells, BMP2 was pre-incubated with a dilution series (from 0.4-100 × the molar concentration of BMP2) of eBMPR1A or eRGMB. After 48 hours incubation, cells were washed with PBS, lysed, and luciferase activity measured using a dual luciferase assay system (Promega) according to the manufacturer's instructions. Luminescence was quantified using a luminometer (Tecan, Infinite 200 PRO). Graphs were produced and statistical tests carried out using GraphPad Prism Version 6.04 (GraphPad Software, La Jolla California USA).
Sample Preparation for microscopy
Prior to imaging 40 nM BMP2 solution was dialyzed against phenol red-free complete DMEM supplemented with 0.1 % FBS to remove 10 mM ammonium acetate buffer. COS7 cells were seeded at a density of 1 × 10 5 cells/ml in glass bottom dishes (2 ml) (MatTek). After 24 hours, cells were transfected with 1.5 μg NEO1-mVenus and 1.5 μg full-length RGMB using Lipofectamine 2000 transfection reagent (Lifetechnologies) according to the manufacturer's protocol. Eight hours post-transfection the cells were serum-starved in phenol red-free complete DMEM supplemented with 0.1% FBS overnight. Prior to imaging cell media was replaced with either 20 nM BMP2-containing media or blank media. Livecell imaging was carried out immediately. For fixed samples, the BMP2 or blank media was removed after the indicated amount of time, cells were fixed with 4 % paraformaldehyde (PFA) (10 min, room temperature) and washed thoroughly in PBS to remove excess PFA before being stored in PBS at 4 °C.
Imaging
Images were acquired on a total internal reflection fluorescence microscope (TIRFM) (ELYRA; Zeiss) with a 100× oil-immersion objective with a numerical aperture of 1.46. For illumination/photoconversion, 30% transmission of the 488-nm laser and 1% transmission of the 405-nm laser were used and 5,000-10,000 images were acquired per sample with a cooled, electron-multiplying charge-coupled device camera (iXon DU-897D; Andor). Exposure time was 300 ms. Recorded images were analyzed with Zeiss ZEN software.
dSTORM Data Processing
Raw fluorescence intensity images were analyzed using the software Zen 2010D (Zeiss MicroImaging). A Gaussian and Laplace filter was applied to each frame, and overlapping events were excluded. An event was classified as originating from a single molecule when I -M > 6S (I is event intensity, M is mean image intensity and S is the s.d. of image intensity). The center of each point-spread function was then calculated by fitting to a two-dimensional Gaussian distribution and a table containing the x-y particle coordinates of each molecule was extracted. Regions of interest, 5 μm × 5 μm or 3 μm × 3 μm in area, containing the twodimensional molecular coordinates were cropped for analysis using Origin (Northhampton, MA, USA), and events with localization precision worse than 60 nm were discarded. Areas containing ~300 molecules for live cell imaging and ~1000 events for the fixed samples were selected. To analyze the spatial point pattern, we used the Ripley's K-function, calculated with SpPack 92 and the Spatstat package for R software 93 , and plotted the Lfunction as described 94, 95 . Briefly, Ripley's K-function is a measure of the number of points encircled by concentric circles of radius r centered on each point. K-values from the Ripley function therefore scale with circle area and so are transformed into the L-function. Using this equation, scaling is linear with the radius. Random distributions have an L(r) value of r over all r values. Therefore to analyze levels of clustering we plotted L(r) against r; and positive values at a given r indicate clustering at that spatial scale. Quantitative cluster maps were generated using Getis and Frankin's analysis as described 94, 95 . Briefly, L(r) values at a spatial scale of 50 nm (L(50)) were computed for each point with R and interpolated using Origin to produce a quantitative cluster map. This was then pseudo-colored with ImageJ 96 to highlight regions of high clustering. Live cell dSTORM images were constructed using a time-gated window approach 97, 98 . On the basis of the frame number from the raw data acquisition, cluster maps were generated from 5000 continuous frames, with each cluster map shifted by 2000 frames relative to the previous one. This corresponded to a time-gated window of ~7 minutes with the clustering analyzed over a total of 30 minutes.
Illustrations
Figures were produced using the programs PYMOL 78 , Adobe Photoshop (Adobe Systems), ImageJ 96 and Corel Draw (Corel Corporation). Sequence alignments were conducted using MULTALIN (bioinfo.genotoul.fr/multalin/multalin.html) and formatted with ESPRIPT (espript.ibcp.fr/ESPript/ESPript/). structure analysis. Superposition of the ternary eRGMB-BMP2-NEO1 FN56 and the active signal conformation of the RGMB-NEO1 FN56 complex (pdb 4BQ6 9 ) using NEO1 (marked with an asterisk) as template, results in a continuous arrangement in which RGMB bridges the dimers of BMP2 and NEO1, respectively. The C-termini of NEO1 and RGMB are marked by black dots. Each structure was determined from one crystal.
a Values in parentheses are for highest-resolution shell.
